Coverage / ZYME / Trade Card

ZYME

Zymeworks Inc

OPPORTUNISTIC BUY Analysis generated 2026-10-04 Market data as of 2026-11-12 Market data 3 days old USD 26.47 Healthcare - BiotechnologyREDUCE ZONE
ACTIONABLEMethodology gates passed
59

Position levels

Currenttoday
USD 26.47
Buy <=wait / entry
USD 18.00
Trim >=take some off
USD 26.00
Thesis breakA 10-K-confirmed failure of the royalty aggregation strategy, a material adverse...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case26%100 / 10026.0
Base case49%62 / 10030.4
Bear case25%10 / 1002.5
Weighted conviction59 / 100 - OPPORTUNISTIC BUY

Top risks

  • Completion of Theravance Biopharma acquisition adding YUPELRI profit-sharing rights
  • 2026 revenue guidance of $278M-$292M and adjusted EBITDA of $114M-$128M post-acquisition
  • YUPELRI profit-share from Viatris collaboration providing immediate accretive cash flow
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n